Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.36 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.36 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.35 |
| ▸ | MGLL | Q99685 | 2/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3792450 | 1.00 | CYP1A2 (0.41) | CYP1A2CHRNB2CHRNA7CHRNA4GBA1 | |
| SCHEMBL31026188 | 1.00 | CYP1A2 (0.41) | CYP1A2CHRNB2CHRNA7CHRNA4GBA1 | |
| SCHEMBL21596445 | 1.00 | CYP1A2 (0.41) | CYP1A2CHRNB2CHRNA7CHRNA4GBA1 | |
| SCHEMBL8333332 | 1.00 | CYP1A2 (0.41) | CYP1A2CHRNB2CHRNA7CHRNA4GBA1 | |
| SCHEMBL7633965 | 0.98 | CYP1A2 (0.39) | CYP1A2CHRNB2CHRNA7CHRNA4GBA1 | |
| SCHEMBL8085940 | 0.93 | ALDH1A1 (0.36) | CYP1A2GBA1 | |
| SCHEMBL28905056 | 0.90 | S1PR1 (0.40) | CYP1A2CHRNB2CHRNA7CHRNA4GBA1 | |
| SCHEMBL28358596 | 0.88 | CHRNB2 (0.46) | CYP1A2CHRNB2CHRNA7CHRNA4GBA1 | |
| SCHEMBL15958842 | 0.87 | CHRNB2 (0.44) | CYP1A2CHRNB2CHRNA7CHRNA4GBA1 | |
| SCHEMBL18068301 | 0.85 | AR (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612216-B2 | Utilizing metal catalyst; one step; low cost | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-11-03 | — | — | US | disclosed |
| EP-1606252-A4 | PRODUCTION OF N-(METHYL-ARYL)-2-LACTAM, N-(METHYL CYCLOAKLYL)-2-LACTAM AND N-ALKYL-2-LACTAM BY REDUCTIVE AMINATION OF LACTONES WITH ARYL AND ALKYCYANO COMPOUNDS | DU PONT (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1606252-A2 | PRODUCTION OF N-(METHYL-ARYL)-2-LACTAM, N-(METHYL CYCLOAKLYL)-2-LACTAM AND N-ALKYL-2-LACTAM BY REDUCTIVE AMINATION OF LACTONES WITH ARYL AND ALKYCYANO COMPOUNDS | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20050148655-A1 | Production of N-(methyl aryl)-2-lactam, N-(methyl cycloalkyl)-2-lactam and N-alkyl-2-lactam by reductive amination of lactones with aryl and alkyl cyano compounds | MANZER LEO E (US) | 2005-07-07 | — | — | US | disclosed |
| US-6906201-B2 | Production of N-(methyl aryl)-2-lactam, N-(methyl cycloalkyl)-2-lactam and N-alkyl-2-lactam by reductive amination of lactones with aryl and alkyl cyano compounds | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2005-06-14 | — | — | US | disclosed |
| WO-2004085047-A2 | PRODUCTION OF N-(METHYL-ARYL)-2-LACTAM, N-(METHYLCYCLOAKLYL)-2-LACTAM AND N-ALKYL-2-LACTAM | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2004-10-07 | — | — | WO | disclosed |
| US-20040192932-A1 | Production of N-(methyl aryl)-2-lactam, N-(Methyl cycloalkyl)-2-lactam and N-alkyl-2-lactam by reductive amination of lactones with aryl and alkyl cyano compounds | E.I. DU PONT NEMOURS AND COMPANY | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148655-A1 | Production of N-(methyl aryl)-2-lactam, N-(methyl cycloalkyl)-2-lactam and N-alkyl-2-lactam by reductive amination of lactones with aryl and alkyl cyano compounds | AAAS, ASNS, NIT2 | CYP1A2 52/4885CHRNB2 2775/4885CHRNA7 2907/4885 |
| US-20040192932-A1 | Production of N-(methyl aryl)-2-lactam, N-(Methyl cycloalkyl)-2-lactam and N-alkyl-2-lactam by reductive amination of lactones with aryl and alkyl cyano compounds | AAAS, ASNS, NIT2 | CYP1A2 52/4885CHRNB2 2775/4885CHRNA7 2907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.